HilleVax, Inc.: Business Overview, Financials & Competitive Analysis
HilleVax, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage vaccine biotech with differentiated VLP platform for norovirus, trading at distressed valuations with near-term cash runway pressure but potential blockbuster upside if Phase 2b data validates efficacy. HilleVax is not currently generating revenue and is considered an early-stage business. The company reduced its cash burn by 28% over the.
What is HilleVax, Inc.'s industry? HilleVax, Inc. (hillevax.com) operates in Biopharmaceutical/Vaccines. AskCyborg classifies HilleVax, Inc. under Biopharmaceutical/Vaccines in its company registry.
HilleVax is a clinical-stage biopharmaceutical company developing and commercializing vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acut...
Cyborg Score thesis
Clinical-stage vaccine biotech with differentiated VLP platform for norovirus, trading at distressed valuations with near-term...
Read the full analyst-debate transcript →Get the Latest HilleVax, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHilleVax, Inc. Overview
Pro stress-test →HilleVax is a clinical-stage biopharmaceutical company developing and commercializing vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products.
Strategic Profile
Pro stress-test →HilleVax's primary focus is its VLP-based vaccine candidate HIL-214, where VLP technology mimics the structure and antigenic properties of viruses without containing infectious genetic material, thereby triggering effective immunogenic responses in the host. As of March 2025, HilleVax had cash of $160m and no debt, with annual cash burn of $90m, providing approximately 21 months of cash runway.
Competitive Landscape
Pro stress-test →Competitors include Moderna, Vaxart, Merck & Co., BioNTech, and CSL Behring. HilleVax differentiates through its specialized VLP platform targeting norovirus, an underserved indication with significant pediatric and geriatric populations. The company faces competition from larger, better-capitalized vaccine manufacturers.
Industry Context
HilleVax, Inc. operates in Biopharmaceutical/Vaccines.
Key facts
Founded: 2019 · Headquarters: Boston, US · Employees: 14 · Market cap: $95M